MITOCHONDRIAL GENETICS AND GENOMICS IN CLINICAL MEDICINE

MITOCHONDRIAL GENETICS AND GENOMICS IN CLINICAL MEDICINE

INTRODUCTION

A number of hereditary disorders present with complex genetic inheritance that do not follow the conventional principles of inheritance as outlined in Chapter 1. There is now overwhelming evidence that some hereditary diseases follow unusual mechanisms that suggest nontraditional inheritance. The mechanisms involve epigenetics (epigenomics), phenotypical effects of genome-wide copy number variation, structural genomic aberrations resulting from non-homologous allelic recombination involving unstable genomic regions flanked by low copy number repeats, and mutations within the mitochondrial DNA (mtDNA) molecule.

Mitochondria are central to cellular energy production and maintenance mediated through oxidative phosphorylation (OXPHOS) in the respiratory chain (RC) that results in oxygen consumption and the production of adenine triphosphate (ATP). These are unevenly distributed across all  organs and body systems except red blood cells. Organs that require rapid and high energy turnover would evidently possess a relatively higher concentration of physiologically active mitochondria; for example, brain, eyes, the vestibulo- cochlear part of the auditory system, endocrine glands, the heart, the liver, the pancreas, the kidneys, and the gastrointestinal tract. Qualitative and quantitative defects in the mitochondrial system are known to be associated with multi-organ and multi-system manifestations (Figure 9.1).

Figure 9.1 Organs involved in mitochondrial  disorders.

The mitochondrial RC includes several proteins encoded by a complex set of DNA sequences distributed across the nuclear and mitochondrial genomes. This chapter outlines the basic components of the mitochondrial genetics that are relevant to systemic clinical medicine. Emphasis is given to complex disorders related to respiratory chain defects. Description and delineation of all mitochondrial diseases are beyond the scope of this chapter; an interested reader or student is encouraged to consult other resources (see “Further Reading”).

RESPIRATORY CHAIN

The mitochondrial respiratory chain (RC) catalyzes the oxidation of fuel molecules by oxygen, and the concomitant energy transduction into adenosine triphosphate (ATP) via five complexes embedded in the inner mitochondrial membrane1 (Figure 9.2). Complex I (CI, dihydronicotinamide adenine dinucleotide dehydrogenase [NADH]-coenzyme Q reductase) carries reducing equivalents from NADH to coenzyme Q (CoQ, ubiquinone) and comprises more than 40 different polypeptides. Complex II (CII, succinate- CoQ reductase) carries reducing equivalents from FADH2 to CoQ and comprises four polypeptides, including the flavine adenine dinucleotide (FAD)-dependent succinate dehydrogenase and iron-sulfur proteins. Complex III (CIII, reduced CoQ-cytochrome c reductase) carries electrons from  CoQ to cytochrome c, and has 11 subunits, while complex IV (CIV, cytochrome c oxidase or COX), the terminal oxidase of the respiratory chain, catalyzes the transfer of reducing equivalents from cytochrome c to molecular oxygen. It is composed of two cytochromes (a and a3), two copper atoms, and 13 different protein subunits.

Figure 9.2 The mitochondrial respiratory chain. CI–CV: complexes I to V. Q:   ubiquinone.

During the oxidation process, electrons are transferred to oxygen via the energy-transducing complexes of the respiratory chain: CI, CIII, and CIV for NADH-producing substrates; CII, CIII, and CIV for succinate; and CIII and CIV for FADH2 derived from the β-oxidation pathway via electron transfer flavoprotein (ETF) and the ETF–CoQ oxidoreductase system. CoQ, a highly hydrophobic quinone, and cytochrome c, a low-molecular-weight hemoprotein, act as “shuttles” between complexes. The free energy generated from the redox reactions is converted into a transmembrane proton gradient. Protons are pumped through CI, CIII, and CIV of the respiratory chain, which creates a charge differential. Complex V (ATP synthase) allows protons to flow back into the mitochondrial matrix and uses the released energy to synthesize ATP. Three ATP molecules are produced from the oxidized NADH.

MITOCHONDRIAL GENETICS

The bulk of the eukaryotic cellular DNA is contained in the nucleus (nuclear DNA, or nDNA). Apart from nDNA, a small amount of DNA is contained in the mitochondria (mtDNA). Mitochondrial RC is made up of about 100 different proteins, only 13 of which are encoded by mitochondrial genes; the rest are encoded by nuclear genes. All of the RC complexes, except CII, have a double genetic origin, and one to seven subunits of the complexes are mitochondrially encoded. In addition, several hundreds of nuclear genes are needed for various RC functions. The result is that the number of mitochondrial proteins represents more than 3% of all cellular proteins.

MITOCHONDRIAL DNA

The mitochondrial genome, in many respects, has more in common with bacterial genomes than with the eukaryotic nuclear genome (Table 9.1). This is consistent with the idea that mitochondria originated as endosymbiotic bacteria within some ancestral eukaryotic cell. If this theory is correct, then over the years the mitochondria have gradually transferred more and more of their functions to the nucleus. Human mitochondrial DNA (mtDNA) is a 16,569 base-pair, closed circular molecule.2 There are no introns, and little intergenic noncoding DNA. Some genes even overlap. Mitochondrion makes a large reticular network and contains several molecules of mtDNA. Each molecule contains 37 genes encoding one large and one small ribosomal RNA (12S rRNA and 16S rRNA, respectively), 22 transfer RNAs (tRNA), and 13 key respiratory chain subunits (Figure 9.3).3 ND1–ND6 are subunits of CI, cytochrome b is the only mitochondrially encoded subunit of CIII, COXI–COXIII are subunits of CIV, and ATP6 and ATP8 are subunits of ATPase (complex V). A short segment of the genome is triple-stranded. The displacement-loop (D-loop) contains the only significant amount of noncoding DNA in the mitochondrial genome. Perhaps because of this, it is the location of many of the DNA polymorphisms that are such useful tools for anthropologists researching the origins of human populations. Because there is no recombination among mitochondrial DNAs, complete haplotypes of polymorphisms are transmitted through the generations, modified only by recurrent mutation, making mtDNA a highly informative marker of ancestry, at least along the maternal line.

Table 9.1 COMPARISON OF NUCLEAR AND MITOCHONDRIAL   GENOMES

NUCLEAR GENOME MITOCHONDRIAL GENOME
Size 3 × 109 bp 16,659 bp
Topology 23 linear molecules 1 circular molecule
No. of genes Ca. 24,000 37
% coding sequence (incl. genes for functional RNAs) Ca. 1.1% 93%
Average gene density Ca. 1 per 125 kb (variable) 1 per 0.45 kb
Introns Average 8 per gene (variable) None
Repetitive DNA Ca. 50% None

Figure 9.3 The heavy (H) and light (L) strands of the circular 16,659 bp mtDNA double helix are  shown. Protein-coding genes are shaded; transfer RNA genes are shown as short lines with the name of the amino acid. There are no introns; the heavy arrows indicate the origins and directions of replication of the two strands; the light arrows show the promoters and direction of transcription of the two multicistronic transcripts that are subsequently cleaved into individual mRNAs. (Adapted with permission from Figure 9.1 of Strachan & Read, Human Molecular Genetics, 3rd edition, London and New York: Garland; 2004).

The   mitochondrion   has    independent   replication,   transcription,   and translation systems. The mitochondrial genome is replicated in two stages. Replication starts at the heavy-strand replication origin (OH) in the D-loop and extends clockwise around the mtDNA. When the light-strand replication origin (OL) is exposed as a single strand, the second strand is then replicated in the opposite direction, starting from OL.4 Thus, replication is bidirectional, but asynchronous. Recently, a new model of mtDNA replication has been proposed in mammals. Replication of mtDNA arises from multiple origins and proceeds via a strand-coupled mechanism.5 The two mtDNA strands are transcribed from specific promoters into two large polycistronic RNAs, which are further processed into ribosomal RNAs (rRNA), transfer RNAs (tRNA), and messenger RNAs (mRNA). All the protein components of the translation machinery are nuclear-encoded, but the rRNAs and tRNAs are exclusively mitochondrially encoded, and these use a coding scheme slightly different from the otherwise universal code. There are two stop codons— UAG and UAA. UGA encodes tryptophan, and AUA is methionin and not isoleucine. Presumably, with only 13 protein-coding genes, the mitochondrial system could tolerate mutations that modified the coding scheme in a way the main genome could not.

During cell division, mitochondria are randomly partitioned into daughter cells (mitotic segregation). Usually, all mtDNA molecules are identical, but, occasionally, a mixture of wild-type and mutant mtDNA is encountered. This is called “heteroplasmy,” whereas “homoplasmy” refers to the occurrence of only one type of mtDNA. In heteroplasmic cells, however, the mtDNA genotype can shift during cell replication. Consequently, some lineages drift toward wild-type mtDNA and become homoplasmic, while others remain heteroplasmic.

The mitochondrial genome is maternally transmitted. Abundant amounts of maternal mitochondria are contained in the ovum cytoplasm, whilst the sperm tail contains the complete male mitochondrial content. At the time of fertilization, all maternal mitochondrial content, including the mutated mtDNA, is passed on wholly in the ovum cytoplasm to the embryo. The sperm-derived paternal mitochondria enter the oocyte cytoplasm after fertilization, but the paternal mtDNA or the paternal mitochondria themselves are then degraded by a variety of mechanisms in order to prevent paternal mtDNA transmission.6 The mother transmits her mtDNA to all her progeny, males and females, and her daughters, in turn, will transmit their mtDNA to the next generation. Theoretically, males never transmit their mtDNA.

NUCLEAR GENES

Genes Encoding Respiratory Chain Subunits

The majority of RC proteins are encoded by nuclear genes. The nuclear- encoded proteins are translated in cytosol and transported across mitochondrial membranes. These nuclear genes are spread out across all human chromosomes on both autosomes and sexual chromosomes. For example, 33 genes of CI subunits have been mapped to various autosomes: one to the X chromosome and seven to mtDNA. Several of these nuclear genes have one or more pseudogenes (non-expressed copies) that can complicate mutation screening in patients.

GENES INVOLVED IN RESPIRATORY CHAIN  ASSEMBLY

The large number of RC proteins and their double genetic origin indicate tightly regulated communication between mitochondria and nuclear compartments. Therefore, in addition to the structural components of the RC, many nuclear-encoded proteins are involved in the assembly  and maintenance of complexes. Most of these genes were first identified in yeast, a model organism for mitochondrial function and dysfunction. Indeed, analysis of yeast mutations resulting in abnormal RC assembly has led to the identification of many of the nuclear products involved in protein folding, stabilization, quality control, membrane translocation, and cofactor addition.7 To date, at least 350 such genes are known in yeast.

GENES INVOLVED IN MTDNA METABOLISM AND MAINTENANCE

Mitochondria possess specific replication, transcription, and repair mechanisms. All of the proteins involved in these mechanisms are encoded by nuclear genes, translated in the cytosol, and then translocated to mitochondria. Only the two rRNAs (12S rRNA and 16S rRNA) and the 22 tRNAs are mitochondrially encoded. Thus far, over 100 genes in yeast are known to result in mtDNA loss when defective.8,9 The proteins involved in mammalian mtDNA maintenance are those directly involved in mtDNA processing,  such  as  DNA  polymerase  γ  (POLG),  Twinkle  helicase,   and mitochondrial transcription factor (TFAM). It has long been claimed that mitochondria have no repair mechanisms, but recent evidence suggests that specific DNA repair processes are present in these organelles.9

GENES INVOLVED IN MITOCHONDRIAL PROTEIN TRANSLATION

Mitochondrial translation requires both mitochondrial and nuclear genes. Mitochondrial DNA encodes rRNA and tRNA, whereas nuclear  genes encode ribosomal proteins, aminoacyl tRNA synthetases, tRNA modification enzymes, and elongation and termination factors. Altogether, several hundreds of proteins are involved in the translation of the 13  proteins encoded by the mitochondrial genome, emphasizing the considerable investment required to maintain the mitochondrial genetic system.10

In addition, a large number of other nuclear genes encode proteins that are not directly related to RC assembly or mtDNA maintenance, but that may interact with them. Mutations in these genes can, therefore, give rise to abnormal RC. Among them are chaperones, proteases, proteins involved in mitochondrial inheritance or morphology, antioxidant enzymes, and various carriers of iron, phosphate, and citrate. As it is commonly assumed that mitochondria contain roughly 1000 different proteins,11 their genes are all possible candidates for mitochondrial disorders.

MITOCHONDRIAL RESPIRATORY CHAIN  DISORDERS

Oxidative phosphorylation is a ubiquitous metabolic pathway that supplies most organs and tissues with energy. Consequently, RC deficiency can theoretically give rise to any symptom in any organ or tissue, and at any age with any mode of inheritance, due to the twofold genetic origin of respiratory enzymes (nuclear DNA and mtDNA). Mitochondrial diseases associated with mtDNA point mutations or large rearrangements have now been characterized, but it should be emphasized that mtDNA mutations represent only a fraction of the genetic causes of these disorders. Indeed, mtDNA encodes only 13 RC subunits, 2 rRNAs, and 22 tRNAs, but several hundreds of proteins involved in various RC function and maintenance are encoded by nuclear genes.

These disorders are characterized by a vast clinical heterogeneity, suggesting high genetic heterogeneity. Yet, although the common feature is RC deficiency, the conditions are due to different enzyme or protein deficiencies. Moreover, the age of onset is highly variable (ranging from the neonatal period to late adulthood), and the deficiency can result in isolated organ deficiency or multivisceral involvement. In the past few years, it has become increasingly clear that genetic defects of oxidative phosphorylation account for a wide variety of clinical symptoms in childhood.12 In general, the diagnosis of RC deficiency is difficult to make on the basis of a single initial symptom, but becomes easier when two or more seemingly unrelated symptoms are observed.

METABOLIC SCREENING FOR RC  DISORDERS

The current screening for RC deficiency includes determinations of plasma lactate, pyruvate, and ketone bodies and their molar ratios as indexes of oxidation/reduction status in cytoplasm and mitochondria, respectively. Persistent hyperlactatemia (>2.5 mM), with elevated lactate/pyruvate     (L/P,>20) and ketone body molar ratios, is highly suggestive of RC deficiency (particularly in the post-absorptive period). When basal screening tests are inconclusive, other tests need to be carried out.12,13

When screening tests are negative, RC deficiency may be misdiagnosed. For this reason, the investigation of patients at risk of RC deficiency should include systematic screening of all possible target organs and tissues, regardless of the onset symptom, as multiple-organ involvement is an important diagnostic clue to RC deficiency.

BIOCHEMICAL DEFECTS IN RC DISORDERS

Diagnostic tests include polarographic and spectrophotometric studies; each provides an independent clue towards the diagnosis of RC deficiency.

Polarographic studies consist of the measurement of oxygen consumption by mitochondria-enriched fractions, using a Clarke electrode in the presence of various oxidative substrates (malate + pyruvate, malate + glutamate, succinate, palmitate, etc.).13 The only limitation of these techniques is the absolute requirement for fresh material: no polarographic studies are possible using frozen material.

Spectrophotometric studies involve isolated or combined respiratory enzyme assays, using specific electron donors and acceptors. These do not require the isolation of mitochondrial fractions and can be carried out on tissue homogenates. For this reason, the amount of material required for enzyme assays (1–20 mg) is very small and can easily be carried out using needle biopsies of liver or kidney, endomyocardial biopsies, or from a pellet of lymphocytes or cultured skin fibroblasts. Samples should be immediately frozen and kept dry in liquid nitrogen (or at –80°C).13

The question of which tissue should be investigated merits particular attention. In principle, the relevant tissue is the one that clinically expresses the disease. Whatever the affected organ, it is mandatory to take skin-biopsy patients (even post mortem) for subsequent investigations using cultured fibroblasts.

RC deficiency associating more than one complex (multiple RC deficiency) is the most frequent cause of mitochondrial disorders in our series of patients (55%). Isolated CI and CIV deficiencies are the second and third causes of these disorders (19% and 13% respectively). A variety of neuromuscular and non-neuromuscular symptoms may be observed, although trunk hypotonia, growth retardation, cardiomyopathy, encephalopathy, and liver failure are the most frequent symptoms. Similar clinical presentations of mitochondrial dysfunction can result from various RC deficiencies or gene mutations, thereby hampering easy classification of these diseases. For example, Leigh syndrome, a subacute necrotizing encephalomyopathy resulting in a devastating encephalopathy, characterized by recurrent attacks of psychomotor regression, with pyramidal and extrapyramidal symptoms, leukodystrophy, and brain-stem dysfunction, may be associated with deficiency of any of the RC complexes and be the result of mutations in either mitochondrial or nuclear genes. Moreover, the mutant genes  can encode structural proteins of RC complexes, proteins involved in the assembly of these complexes, or proteins involved in the process of mitochondrial translation. On the other hand, in most cases, mutations of a specific gene lead to a relatively homogeneous clinical presentation. Thus, elucidating the genetic bases of RC is essential for both the genetic diagnosis of patients and our fundamental knowledge of these disorders, a prerequisite of any therapy-based research.

GENETICS OF MITOCHONDRIAL RESPIRATORY CHAIN DISORDERS

Mitochondrial RC disorders are genetically heterogeneous. Indeed, the RC is made up of around 100 polypeptides encoded by as many different genes. These genes are either nuclear or mitochondrial. In addition, the biogenesis and assembly of all these polypeptides require several dozens of nuclear genes, some of which are found only in humans. Mitochondrial RC disorders can result from a mutation of any one of these hundreds of genes. Thus, all modes of inheritance may be encountered in mitochondrial RC disorders: sporadic cases due to mtDNA mutations or nuclear gene mutations; maternal transmission in the case of mtDNA mutations; and autosomal recessive, autosomal dominant, or X-linked inheritance. Unfortunately, in only a few patients (25% in our series) have the disease-causing mutations been identified (Figure 9.4). Nevertheless, mtDNA mutations have been systematically excluded in most patients with unknown mutations, suggesting that in these cases the mitochondrial disease is due to a nuclear  gene mutation.

Figure 9.4 Distribution of mtDNA and nDNA mutations in RC deficiency in Necker Hospital   (Paris).

MITOCHONDRIAL DNA MUTATIONS

Pathological alterations of mtDNA fall into three major categories: point mutations; deletion-duplications; and copy-number mutations (depletions). In most cases, mtDNA mutations are heteroplasmic, as both normal and mutant mtDNA are present. In cells harboring both mutant and wild-type molecules, the phenotype is a reflection of the proportion of mutant mtDNA molecules and the extent to which the cell type relies on mitochondrial function. Point mutations include amino-acid substitutions and protein-synthesis mutations (tRNA, rRNA) (Table 9.2).

Mitochondrial protein-Synthesis point mutations

The A3243G mutation in the tRNALeu gene is responsible for the MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) syndrome.14 MELAS is characterized by onset in childhood with intermittent hemicranial headache, vomiting, proximal limb weakness, recurrent neurological deficit resembling stroke (hemiparesis, cortical blindness, hemianopsia), lactic acidosis, and, occasionally, ragged red fibers on muscle biopsy. Computed tomography (CT) brain imaging shows low- density areas (usually posterior) that may involve both white and gray matter, but that do not always correlate with clinical symptoms or vascular territories The pathogenesis of stroke-like episodes in MELAS has been ascribed to either cerebral blood flow disruption or acute metabolic decompensation in biochemically deficient areas of the brain.

The A3243G mutation also causes the maternally inherited insulin- dependent diabetes mellitus and deafness (MIDD) that may also complicate with dilated cardiomyopathy.15

The A8344G missense mutation in the mt tRNALys gene accounts for 80% of cases of MERRF (myoclonus epilepsy with ragged red fibers).16 This disease is characterized by encephalomyopathy with myoclonus, ataxia, hearing loss, muscle weakness, and generalized seizures.

Also, several other mutations of either tRNA or rRNA genes have been reported in non-related families.3

Mutations in protein-Coding genes

The most frequent mutations in mitochondrial genes encoding structural proteins have been reported in LHON (Leber hereditary optic neuropathy) and in NARP (neurogenic, ataxia, and retinitis pigmentosa)/Leigh syndrome.3 These mutations are recurrent mutations, as numerous non-related patients harbor these mutations. Other mutations have also been described in  a number of genes, but these are most often restricted to a specific patient or family.

NARP, and variable sensory neuropathy, seizures, and mental retardation, are due to an amino-acid change in the ATPase6 gene (T8993G).17

LHON is  associated with  rapid bilateral central vision  loss due to   optic-nerve death. Cardiac dysrhythmia is frequently associated with the disease, but no evidence of skeletal muscle pathology or gross  structural mitochondrial abnormality has been documented. The median age for vision loss is 20–24 years, but it may occur at any time between adolescence and late adulthood. Expression among maternally related individuals is variable, and there is a bias towards affecting males. To date, 90% of LHON cases harbor one of the three primary mutations (G11778A, T14484C, G15257A), although several other missense mutations—called “secondary mutations”— in the mtDNA can act autonomously or in association with each other to cause the disease.3

CI deficiency is the most frequent cause of mitochondrial disorders, having been found in more than 30% of patients. Trunk hypotonia, antenatal and postnatal growth retardation, encephalopathy, and liver failure are the main clinical features.18,19 Systematic sequencing of the mitochondrial CI genes has shown that around 20% of CI-deficient patients harbored point mutations in one of these genes—at least, in our series.

In contrast, CIII deficiency is a relatively rare cause of respiratory enzyme dysfunction. Indeed, in our experience, of all RC enzyme-deficient patients, only 7% had a CIII deficiency.20 However, the clinical presentation of CIII- deficient patients is highly heterogeneous, including myopathy, encephalomyopathy, multi-organ disorders, cardiomyopathy, tubulopathy, and intrauterine growth retardation.20,21 This complex contains 11 subunits, and only one, cytochrome b (cytb), is of mitochondrial origin. So far, 12 cytb mutations   have   been   described   in   association   with   various     clinical presentations. Interestingly, in most patients (8/12), the predominating presenting feature was severe exercise intolerance, sometimes including muscle weakness and/or myoglobinuria.22 Two other patients presented with cardiomyopathy, another patient had encephalomyopathy, and a further patient had MELAS and an akinetic rigid syndrome.

Cytochrome c oxidase (COX) deficiency is a frequent cause of  RC disorder in childhood and is clinically heterogeneous, with phenotypes such as encephalomyopathy, Leigh syndrome,23 fatal and benign infantile myopathy, hepatic failure,24 and myoglobinuria.25 In fact, mtDNA mutations have been identified in patients with various clinical presentations. These mutations have been described in the three mitochondrial COX genes (COXI, COXII, COXIII),3 and have always been associated with single pedigrees and are, therefore, private mutations. Most patients with mtDNA COX mutations have muscle-related or neuromuscular symptoms. However, mutations of COXI have also been reported in two cases of acquired  sideroblastic anemia.26

Most of these mutations are maternally inherited and heteroplasmic, and associated with a striking variety of clinical phenotypes, depending on the proportion of mutant mtDNA inherited among the maternal relatives. Within one particular pedigree, clinical presentations can range from migraines and attention-deficit disorders to the full MELAS syndrome. Maternal relatives of patients are generally healthy as long as they have no more than 85% mutant mtDNA. Once the percentage of mutant mtDNA rises beyond this level, there are increasingly serious consequences for the clinical phenotype, thus highlighting the sharp threshold in protein-synthesis mutations.

Large-Scale mtDNA rearrangements

The second category of mtDNA diseases is deletion of the mitochondrial genome. Although the size and position of the deletion differ markedly among patients, they usually encompass several encoding and tRNA genes. They are usually sporadic, heteroplasmic, and unique, and frequently occur between directly repeated sequences, suggesting that they are caused by de novo rearrangements arising during oogenesis or early development.

The Kearns–Sayre syndrome (KSS) is a multisystem  disorder characterized  by  a  non-variable  triad:  onset  before  age  20;    progressive external ophthalmoplegia; and pigmentary retinal degeneration, plus at least one of the following: complete heart block, cerebrospinal fluid (CSF) protein>100 mg/dL, and/or cerebellar ataxia. Large-scale heteroplasmic mtDNA deletions are frequently detected in skeletal muscle.27

Pearson syndrome comprises refractory sideroblastic anemia, with variable neutropenia and thrombocytopenia, vacuolization of marrow precursors, and exocrine pancreatic dysfunction. Severe transfusion-dependent macrocytic anemia begins in early infancy (before age one year) and is fatal by three years of age in 62% of cases. The patients who survive spontaneously recover from their myelodysplasia, but usually develop KSS. Large-scale heteroplasmic mtDNA deletions are present in all tissues, with the ratio of normal-to-deleted genomes being related to expression of the disease.28

Progressive external ophthalmoplegia (PEO) is a mitochondrial myopathy with progressive muscle weakness and external ophthalmoplegia. Ataxia, episodic ketoacidotic coma, and early death have also been reported. Large- scale mtDNA deletions are found in the skeletal muscle of the patients.29

Few patients with syndromic diabetes also present with mtDNA deletions. In most cases, the deletion is maternally inherited and always heteroplasmic. Diabetes is frequently associated with deafness, but may also be part of a multi-organ disorder.3033 It is worthwhile noting that the most common deletion (4977 bp), found in 30% of patients harboring a unique deletion, flanked by 13-bp direct repeats, has been described in both Pearson syndrome and KSS, and subsequently also reported in PEO. Thus, no correlation can be found between clinical presentation and the nature or extent of the rearrangements. Finding progressive organ involvement should prompt the suspicion of a diagnosis of mtDNA rearrangement, and lead to long-range polymerase chain reaction (PCR) or Southern blot analyses on total DNA.

Quantitative (depletion) and qualitative (multiple deletion) mtDNA anomalies may also be due to mutations of nuclear genes involved in mtDNA maintenance. In such cases, the disease is inherited as an autosomal dominant or recessive trait (see below).

Table 9.2 COMMON CLINICALLY RECOGNIZABLE MITOCHONDRIAL DISORDERS ASSOCIATED WITH MTDNA  MUTATIONS

So far, no mitochondrial disease has been exclusively associated with any population-specific subgroup. However, it is likely that mtDNA mutations and/or polymorphisms are important in disease causation when they occur in association with either heterozygous or homozygous nuclear DNA mutations.

NUCLEAR DNA MUTATIONS

The number of disease-causing mutations in nuclear genes is steadily growing, and these mutations probably underlie the vast majority of RC deficiencies. It should be borne in mind that mtDNA deletions and mutations account for no more than 15–20% of cases, at most, among pediatric patients. Thus, in most cases, nuclear gene defects are those most likely to be responsible for RC deficiency.

Indeed, proper RC functioning requires not only the presence of various subunits of each complex, but also ancillary proteins at different stages of holoenzyme biogenesis, including transcription, translation, chaperoning, addition of prosthetic groups, and assembly of proteins, as well as various enzymes involved in mtDNA metabolism.

DEFECTS IN STRUCTURAL RESPIRATORY CHAIN GENES

The various nuclear genes encoding RC subunits have all been identified and mapped, and mutations of some of these genes have been found in patients. Interestingly, most of the mutations encountered have been in CI genes; whereas, despite the concerted efforts of various teams of researchers, very few mutations in other genes encoding other complex subunits have been found.

The first mutation in a gene encoding an RC subunit was reported in 1995 in two sisters with Leigh syndrome and CII deficiency. The pathogenic mutation was in the SDHA gene encoding the flavoprotein of  CII.34 Mutations in the same gene were subsequently reported in another patient who also presented with Leigh syndrome.35,36 However, only a few patients with CII deficiency have been molecularly characterized, despite systematic study of the four genes encoding the CII subunits, suggesting that these deficiencies could be due to mutations in assembly proteins. Nevertheless, mutations of the three other genes encoding subunits B, C, and D of CII have been reported in hereditary paraganglioma and phaeochromocytoma, suggesting that such “housekeeping” genes may be involved in carcinogenesis.37 It is hypothesized that succinate dehydrogenase (SDH) mutations cause an accumulation of succinate and reactive oxygen species (ROS), which could act as downstream signaling molecules to activate hypoxia-inducing pathways.37

The pioneering work by Smeitink and colleagues in the Netherlands identified the first molecular bases of CI deficiencies.19 This complex is the largest RC complex, and consists of seven mitochondrial-encoded and at least 35 nuclear-encoded proteins. CI deficiency is one of the most common causes of mitochondrial disease. Screening of the various structural CI genes by several teams has allowed the identification of mutations in conserved subunits of this complex, and the findings show that around 40% of CI deficiencies are related to mutations in those genes. Most of the patients presented with Leigh or Leigh-like syndrome, although cardiomyopathy has also been reported (Figure 9.5).

Figure 9.5 Gene mutations resulting in specific respiratory chain complexes. Genes encoding for the subunits of complexes and assembly factors are shown in the upper and lower registers, respectively. Genes in boldface are mutations found in several patients or  families.

Mutations in only two genes encoding CIII subunits, UQCRB  and UQCRQ, have been reported,38,39 as have the two genes encoding CIV subunits, COX4I240 and COX6B1.41 However, no mutation of any of the nuclear genes in complex V has been described, whereas several mutations in its mitochondrial genes have been reported (Figure 9.5).

GENES INVOLVED IN RC ASSEMBLY

The various RC complexes contain four (CII) to 45 subunits (CI) each. Therefore, a functional complex requires structural integrity and tight regulation of each of its subunits and cofactors. Alterations in any of the mechanisms allowing structural integrity in these complexes may result in catalytic dysfunction or instability of the complex assembly. These mechanisms include architectural assembly of complex subunits, incorporation of cofactors, translation of specific subunits, and heme, iron, or copper assembly. Several of these assembly factors have been identified in humans by homology with their yeast counterparts. Also, searching for disease-causing genes in patients has led to the identification of new human genes involved in these mechanisms.

CI, the largest RC complex, has several assembly factors (NDUFAF1, NDUFAF2, C6orf66, C8orf38, and C20orf7) that have been identified in humans as a result of studying patients.19 As yet, however, the exact function of these genes is unknown (Figure 9.5).

CII deficiency represents a rare cause of mitochondrial disorders, although, recently, two genes involved in its assembly have been found in humans. By homozygosity mapping and candidate-gene analyses, mutations in the SDHAF1 gene were identified in patients with infantile leukoencephalopathy and isolated CII deficiency.42 SDHAF1 mutations lead to reduced amounts of the complex. SDH5 is a mitochondrial protein gene required for flavination of the SDH1 subunit, and mutations of the gene have been found in paraganglioma.43

Only two genes involved in CIII assembly are known in humans. The gene BCS1L allows the assembly of the iron-sulphur protein subunit in the complex. BCS1L mutations have been identified in three clinical entities associated with CIII deficiency: one group of patients presents with tubulopathy and hepatic failure44; another group has the GRACILE (growth retardation, aminoaciduria, cholestasis, iron overload, lactacidosis and early death) syndrome45; and the final group presents with the Björnstad syndrome (sensorineural hearing loss and pili torti)46 (Figure 9.5). The TTC19 gene encodes tetratricopeptide 19, a new assembly factor of CIII. Mutations of this gene results in severe neurological abnormalities.47

Using different approaches in patients with COX deficiency, such as gene-mapping, functional complementation, or candidate gene studies, several assembly genes have been identified as disease-causing. SURF1 represents a major gene for Leigh syndrome associated with COX deficiency, with 25– 75% of Leigh–COX patients having SURF1 mutations.48 It has also recently been shown that SURF1 in bacteria is a heme-binding protein that may be involved in heme insertion in cytochrome oxidase.49 COX10 encodes heme A:farnesyltransferase, catalyzing the first step in the conversion of protoheme to the heme A prosthetic group required for cytochrome c oxidase activity, while COX15 allows the hydroxylation of heme O to form heme A. However, few patients present with mutations of these two genes, thereby hindering any genotype–phenotype correlation. COX15 mutations lead to  cardiomyopathy or Leigh syndrome,5052 whereas COX10 mutations are associated with tubulopathy and leukodystrophy.53,54 Mutations in SCO155 and  SCO2 genes,56 both of which are involved in mitochondrial copper maturation and synthesis of subunit II of COX,57 also give rise to hepatopathy and ketoacidotic coma (SCO1) and cardiomyopathy (SCO2). Mutations in LRPPRC cause Leigh syndrome, French-Canadian type.58 The LRPPRC protein is thought to be involved in the translation or stability of the mRNA of subunits I and III of COX.59 FASTKD2 mutations, reported in only one kindred, cause encephalomyopathy and convulsions.60 Although the gene is not directly involved in the assembly of CIV, it may play a role in the regulation of mitochondrial apoptosis (Figure 9.5). TACO1 is a recently identified gene of COX deficiency that encodes a translational activator of the COX1 subunit encoded by mtDNA. Mutations of this gene result in late- onset Leigh syndrome.61 Finally, C12orf62 is required for coordination of the early steps of COX assembly and mutations in this gene result in fatal neonatal lactic acidosis.62

Most complex V deficiencies are associated with mtDNA mutations (ATP6 and ATP8 gene mutations), and only two complex V nuclear mutations have been reported. The ATP12 gene encodes a protein required for assembly of the alpha and beta subunits, and mutations of this gene, reported in one patient, resulted in dysmorphic features, neurological involvement, and methylglutaconic aciduria.63 A large kindred of Gipsy origin with isolated complex V deficiency and neonatal encephalocardiomyopathy were reported to present with mutations in TMEM70, a gene encoding a transmembrane mitochondrial protein of yet unknown function involved in the assembly of complex V64 (Figure 9.5).

Several proteins of the RC are iron-sulphur proteins, and deficiencies in the assembly of the iron-sulphur cluster have been reported to result in dysfunction of CI, CII, and CIII, which contain iron-sulphur proteins. Indeed, Friedreich’s ataxia, one of the most common forms of autosomal recessive ataxia, associated with hypertrophic cardiomyopathy and diabetes in 10% of cases, is due to a mutation of frataxin, a mitochondrial protein involved in iron-sulphur protein biogenesis.65 Mutations on the iron-sulphur cluster scaffold protein (ISCU), which interacts with frataxin in iron-sulphur cluster biosynthesis, lead to myopathy, with exercise intolerance and myoglobinuria.66,67

Electron transfer along the RC depends on a quinone pool synthesized in the mitochondria. Deficiencies in several enzymes or proteins (PDSS1, PDSS2, COQ2, COQ9, CABC1) involved in this biosynthesis pathway are reported to be associated with various clinical presentations6870 (Figure 9.5).

GENES INVOLVED IN MTDNA STABILITY

Mitochondrial DNA is packaged into protein–DNA complexes called “nucleoids.” Nucleoids in cultured mammalian cells contain 5 to 10 mtDNA molecules and appear to be tethered to the inner mitochondrial membrane. Although their protein composition remains controversial, it is now well established that nucleoids contain the mtDNA replisome.71 Crucial  proteins or enzymes involved in either mtDNA replication (mtDNA polymerase γ, mtSSB, Twinkle helicase) or transcription (TFAM) are also components of nucleoids. In theory, defects in any of the proteins involved in mtDNA replication can affect mtDNA copy number. Such replication is also highly dependent on the mitochondrial deoxyribonucleotide triphosphate (dNTP) supply, suggesting that mutations in several genes involved in mitochondrial dNTP synthesis may, therefore, result in mtDNA anomalies (Figure 9.6).

Figure 9.6 Mitochondrial DNA replication and translation of proteins encoded by mtDNA. The gene mutations resulting in mitochondrial diseases and multiple respiratory chain deficiencies are shown in the black ovals.

Autosomal-dominant external ophthalmoplegia (adPEO) is associated with multiple mtDNA deletions,72 which are restricted to muscle tissue. With an onset in adulthood, adPEO includes progressive weakness of the extraocular muscles as a cardinal feature; patients have ptosis and limited  eye movements, with additional features varying from one family  to another. Most cases of adPEO associated with multiple mtDNA deletions are due to mutations in POLG1 (mtDNA polymerase γ),73 POLG2,74 ANT1 (mitochondrial ADP/ATP translocator),75 PEO1 (Twinkle helicase)76 and OPA1, a dynamin-related GTPase involved in mitochondrial  fusion77(Figure9.6). In rare cases, the disease is autosomal-recessive.

Mitochondrial DNA depletion syndrome (MDS) was initially described as “congenital myopathy” or “hepatopathy.”78 Since then, however, many patients have demonstrated different clinical presentations, including hepatocerebral, myopathic, and encephalomyopathic forms.79,80 In such patients, there is a marked (usually tissue-specific) deficiency in mtDNA levels, with a residual amount of mtDNA that is often less than 10% of normal values. Such depletion leads to deficiencies of multiple RC complexes, while nuclear-encoded components such as CII are mostly expressed normally. Depletion is related to abnormal mtDNA replication, especially defects in dNTP supply and replication mechanisms. Mutations in POLG and PEO1 encoding the Twinkle helicase, two replication factors, are associated with severe and often fatal hepatocerebral forms81 and/or Alpers’ syndrome,82 characterized by psychomotor retardation, intractable epilepsy, and liver failure in infants and young children. Hepatocerebral forms are also associated with the DGUOK gene,83 which encodes the mitochondrial deoxyguanosine kinase involved in the salvage pathway of dNTP for mtDNA synthesis, or the MPV17 gene, which encodes a protein of unknown function.84 The TK2 gene encodes mitochondrial thymidine kinase, which is also involved in mitochondrial dNTP salvage. Mutations of this gene are associated with severe infantile myopathy85 and, recently, with motor neuron disease resembling spinal muscular atrophy,86 encephalopathy or seizures, cardiomyopathy, or dystrophic changes in muscle.87 Synthesis of mtDNA requires not only sufficient mitochondrial dNTP pools, but also balanced cytosolic dNTP synthesis. Indeed, mutations of RRM2B encoding a small subunit of cytosolic ribonucleotide reductase, the enzyme that catalyzes dNDP synthesis from nucleotide diphosphate (NDP), results in severe muscle mtDNA depletion and neonatal trunk hypotonia, with hyperlactatemia.88 Mutations of two subunits of the succinyl-CoA synthase (SUCLA2, SUCLG1) have been reported in patients with mild mtDNA depletion. SUCLA2 patients present with psychomotor retardation, muscle hypotonia, hearing impairment, and seizures,89 whereas those with SUCLG1 mutations have encephalomyopathy and methylmalonic aciduria.90 Although both these mutations lead to methylmalonic aciduria, the pathogenesis of this condition is poorly understood.

Mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome is a multisystem disorder clinically characterized by onset between the second and fifth decades of life, ptosis, PEO, gastrointestinal dysmotility, diffuse leukoencephalopathy, peripheral neuropathy, and myopathy. Patients may have multiple mtDNA deletions and/or mtDNA depletion. The disease- causing gene (TP) encodes thymidine phosphorylase.91 Mutations  of this gene can affect the balance of the intramitochondrial dNTP pool and lead to mtDNA deletions and depletion.80

Interestingly, it is becoming more and more evident that mutations of a same gene can be associated with various clinical presentations and result in either quantitative or qualitative mtDNA anomalies. In addition, the inheritance of the associated diseases may be either dominant or recessive. Indeed, POLG and PEO1 mutations can lead to either adPEO with multiple mtDNA depletion, or a fatal, recessive, hepatocerebral form with severe mtDNA depletion. On the other hand, RRM2B mutations, which usually cause severe muscle mtDNA depletion in neonates, have been recently associated with adPEO, with multiple mtDNA deletions,92 and with MNGIE syndrome in adult patients.93

Genes involved in translation of mtDNA-Encoded  proteins

Mitochondria contain separate protein-synthesis mechanisms allowing the synthesis of polypeptides encoded by mtDNA. The process not only requires tRNA and rRNA encoded by mtDNA, but also hundreds of nuclear genes encoding ribosomal proteins, aminoacyl-tRNA synthetases, tRNA modification enzymes, rRNA base-modification enzymes, and elongation and termination factors10 (Figure 9.6). Mutations in several of these factors have been reported in patients with multiple RC deficiencies and various clinical presentations, such as myopathy and sideroblastic anemia (PUS1, YARS2)94,95; leukoencephalopathy (DARS2)96; pontocerebellar hypoplasia (RARS2)97; cardiomyopathy (AARS2)98; hyperuricemia, pulmonary hypertension, and renal failure (SARS2)99; Perrault syndrome (HARS2)100; encephalomyopathy (TSFM)101; hypertrophic cardiomyopathy (TSFM)101; hepatoencephalopathy (GFM1)102; infantile encephalopathy (EFTu)103; fatal neonatal lactic acidosis (MRPS16)104; multivisceral involvement (MRPS22)105;   hypertrophic   cardiomyopathy   (MRPL3)106;   hepatic failure (TRMU)107; Leigh syndrome (MTFMT)108; and spastic ataxia (MTPAP).109 Considering the large number of patients with multiple RC deficiencies without mtDNA anomalies, it may be hypothesized that such cases may be related to abnormal translation due to nuclear gene deficiency.

GENETIC COUNSELING AND PRENATAL  DIAGNOSIS

Prenatal diagnoses of mitochondrial disorders fall in two categories, depending on the nature of the identified mutation. If the disease is related to a nuclear gene mutation, mutation screening using a sample of chorionic villi at 10 weeks of gestation offers early and reliable prenatal diagnosis. Identification of an mtDNA mutation in the proband should always prompt examination and testing of the patient’s maternal relatives for the mutation. In cases of maternal inheritance of mtDNA mutations (or deletions), there is no risk for the progeny of an affected male. The risk is high, however, for the progeny of carrier females. In this case, prenatal diagnosis based on chorionic villi or amniotic cells represents a rational approach to the prevention of these serious disorders. Nevertheless, prevention is currently hampered by our incomplete knowledge the actual proportion of mutant mtDNA, its relationship to disease severity, and its random tissue distribution and selection in the affected population during development, which may also be related to various metabolic activities. Indeed, it would be difficult to make an accurate prediction of the age of onset and the phenotype in any offspring of an affected mother. The pedigree (Figure 9.7) illustrates variable severity of MELAS in terms of myopathy, myoclonic epilepsy, deafness, and dementia. According to the data so far, having a percentage of mutant mtDNA less than 30% or greater than 80% is predictive of a reasonable chance of a good or bad prognosis, respectively.110 Any results in between these limits would be of even less certain predictive value. But whatever the results, any studies aimed at prenatal diagnosis or predictive genetic guidelines require careful validation, as the proportions of mutant mtDNA may change not only between fetal life and infancy, but also throughout adulthood.

Figure 9.7 Segregation of variable clinical phenotypes in a family with multi-system mitochondrial disorder similar to myoclonic epilepsy lactic acidosis with strokelike symptoms   (MELAS).

Recent reports surrounded by intense ethical and moral debate have led to acceptance of the challenging approach for preventing recurrence of a mitochondrial disease through allowing the embryo to be nurtured in wild mitochondrial  environment.109   This  method,  essentially  described  as “the three-parent offspring,” involves creating the embryo through in vitro fertilization of the ovum from an affected woman with her partner’s sperm (or any other source). The embryo is then removed and transferred to an enucleated ovum from another woman (Figure 9.8). Essentially, the resulting embryo would contain the complete set of biological parents’ nuclear DNA and mtDNA from another woman (see Chapter 46, on reproductive medicine, for further details). The technique, undoubtedly exciting and technically feasible, has led to intense public and medial debate. The United Kingdom’s Parliament is considering an amendment to the existing Human Embryology and Fertilization Act to make this method legal.

Figure 9.8 Prevention of transmission of mutated maternal mtDNA through transfer of in vitro embryo into an enucleated ovum with wild  mtDNA.

SUMMARY

Mitochondrial disorders are due to respiratory chain deficiency. Oxidative phosphorylation—ATP synthesis by the oxygen-consuming respiratory chain (RC)—supplies most organs and tissues with a readily usable energy source and is already fully functioning at birth. This means that, in theory, RC deficiency can give rise to any symptom in any organ or tissue at any age and with any mode of inheritance, due to the twofold genetic origin of RC components (nuclear DNA and mitochondrial DNA). It has long been erroneously believed that RC disorders originate from mutations of mtDNA, as, for some time, only mutations or deletions of mtDNA could be identified. However, the number of known disease-causing mutations in nuclear genes is now steadily growing. These genes not only encode the various subunits of each complex, but also the ancillary proteins involved in the different stages of holoenzyme biogenesis, including transcription, translation, chaperoning, addition of prosthetic groups, and assembly of proteins, as well as the various enzymes involved in mtDNA metabolism.

The increasing number of abnormal mitochondrial functions and genes leading to RC deficiency continues to shed light on the clinical heterogeneity of mitochondrial disorders. The identification of the disease-causing genes is important not only for genetic counseling and prenatal diagnosis, but also for a greater understanding of the pathophysiology of these disorders. However, the ever-increasing numbers of genes found to be involved in mitochondrial functions and possibly mitochondrial diseases require the development of large-scale, high-throughput technologies that can increase our insight into these highly complicated pathologies.

REFERENCES

1.   Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem. 1985;54:1015–1069.

2.   Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290: 457–465.

3.   Ruiz-Pesini E, Lott MT, Procaccio V, et al. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res. 2007;35:D823– D828.

4.   Clayton DA. Mitochondrial DNA replication: what we know. IUBMB Life. 2003;55:213–217.

5.   Yang MY, Bowmaker M, Reyes A, et al. Biased incorporation of ribonucleotides on the mitochondrial L-strand accounts for apparent strand-asymmetric DNA replication. Cell. 2002;111:495–505.

6.   Luo SM, Sun QY. Autophagy is not involved in the degradation of sperm mitochondria after fertilization in mice. Autophagy. 2013;9:2156–2157.

7.   Grivell LA, Artal-Sanz M, Hakkaart G, et al. Mitochondrial assembly in yeast. FEBS Lett. 1999;452:57–60.

8.   Contamine V, Picard M. Maintenance and integrity of the mitochondrial genome: a plethora of nuclear genes in the budding yeast. Microbiol Mol Biol Rev. 2000;64:281–315.

9.   Bogenhagen DF. Repair of mtDNA in vertebrates. Am J Hum Genet. 1999;64:1276–1281.

10.    Jacobs HT, Turnbull DM. Nuclear genes and mitochondrial translation: a new class of genetic disease. Trends Genet. 2005;21:312–314.

11.    Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134:112– 123.

12.    Munnich A, Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet. 2001;106:4–17.

13.    Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994;228:35–51.

14.    Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348:651–653.

15.    van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992;1:368– 371.

16.    Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell. 1990;61:931–937.

17.   Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet. 1990;46:428–433.

18.    Benit P, Chretien D, Kadhom N, et al. Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency. Am J Hum Genet. 2001;68:1344–1352.

19.        Distelmaier F, Koopman WJ, van den Heuvel LP, et al. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain. 2009;132:833–842.

20.    von Kleist-Retzow JC, Cormier-Daire V, de Lonlay P, et al. A high rate (20%–30%) of parental consanguinity in cytochrome-oxidase deficiency. Am J Hum Genet. 1998;63:428–435.

21.    Valnot I, Kassis J, Chretien D, et al. A mitochondrial cytochrome b mutation but no mutations of nuclearly encoded subunits in ubiquinol cytochrome c reductase (complex III) deficiency. Hum Genet. 1999;104:460–466.

22.    Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med. 1999;341:1037–1044.

23.   Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol. 1996;39:343–351.

24.    Cormier V, Rustin P, Bonnefont JP, et al. Hepatic failure in disorders of oxidative phosphorylation with neonatal onset. J Pediatr. 1991;119:951– 954.

25.    DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol. 2006;18:636–641.

26.   Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood. 1997;90:4961–4972.

27.    Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature. 1988;331:717–719.

28.    Rotig A, Cormier V, Blanche S, et al. Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest. 1990;86:1601–1608.

29.        Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;320:1293–1299.

30.   Souied EH, Sales MJ, Soubrane G, et al. Macular dystrophy, diabetes, and deafness associated with a large mitochondrial DNA deletion. Am J Ophthalmol. 1998;125:100–103.

31.   Rotig A, Bessis JL, Romero N, et al. Maternally inherited duplication of the mitochondrial genome in a syndrome of proximal tubulopathy, diabetes mellitus, and cerebellar ataxia. Am J Hum Genet. 1992;50:364–370.

32.    Nicolino M, Ferlin T, Forest M, et al. Identification of a large-scale mitochondrial deoxyribonucleic acid deletion in endocrinopathies and deafness: report of two unrelated cases with diabetes mellitus and adrenal insufficiency, respectively. J Clin Endocrinol Metab. 1997;82:3063–3067.

33.   Paquis-Flucklinger V, Vialettes B, Vague P, et al. Importance of searching for mtDNA defects in patients with diabetes and hearing deficit. Diabetologia. 1998;41:740–741.

34.   Bourgeron T, Rustin P, Chretien D, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet. 1995;11:144–149.

35.    Parfait B, Chretien D, Rotig A, Marsac C, Munnich A, Rustin P. Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome. Hum Genet. 2000;106:236–243.

36.    Horvath R, Abicht A, Holinski-Feder E, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry. 2006;77:74–76.

37.   Baysal BE. Clinical and molecular progress in hereditary paraganglioma. J Med Genet. 2008;45:689–694.

38.    Haut S, Brivet M, Touati G, et al. A deletion in the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic acidosis. Hum Genet. 2003;113:118–122.

39.        Barel O, Shorer Z, Flusser H, et al. Mitochondrial complex III deficiency associated with a homozygous mutation in UQCRQ. Am J Hum Genet. 2008;82:1211–1216.

40.    Shteyer E, Saada A, Shaag A, et al. Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene. Am J Hum Genet. 2009;84:412–417.

41.    Massa V, Fernandez-Vizarra E, Alshahwan S, et al. Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am J Hum Genet. 2008;82:1281–1289.

42.   Ghezzi D, Goffrini P, Uziel G, et al. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet.2009

43.   Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139–1142.

44.    de Lonlay P, Valnot I, Barrientos A, et al. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency  in patients with tubulopathy, encephalopathy and liver failure. Nat Genet. 2001;29:57–60.

45.    Visapaa I, Fellman V, Vesa J, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet. 2002;71:863–876.

46.    Hinson JT, Fantin VR, Schonberger J, et al. Missense mutations in the BCS1L gene as a cause of the Bjornstad syndrome. N Engl J Med. 2007;356:809–819.

47.    Ghezzi D, Arzuffi P, Zordan M, et al. Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies. Nat Genet. 2011;43:259–263.

48.   Sue CM, Karadimas C, Checcarelli N, et al. Differential features of patients with mutations in two COX assembly genes, SURF-1 and SCO2. Ann Neurol. 2000;47:589–595.

49.        Bundschuh FA, Hannappel A, Anderka O, Ludwig B. SURF1, associated with Leigh syndrome in humans, is a heme-binding protein in bacterial oxidase biogenesis. J Biol Chem. 2009;284:25735–25741.

50.   Antonicka H, Mattman A, Carlson CG, et al. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early- onset fatal hypertrophic cardiomyopathy. Am J Hum Genet. 2003;72:101– 114.

51.    Oquendo CE, Antonicka H, Shoubridge EA, Reardon W, Brown GK. Functional and genetic studies demonstrate that mutation in the COX15 gene can cause Leigh syndrome. J Med Genet. 2004;41:540–544.

52.    Bugiani M, Tiranti V, Farina L, Uziel G, Zeviani M. Novel mutations in COX15 in a long surviving Leigh syndrome patient with cytochrome c oxidase deficiency. J Med Genet. 42, e28.2005

53.    Valnot I, von Kleist-Retzow JC, Barrientos A, et al. A mutation in the human heme A:farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum Mol Genet. 2000;9: 1245–1249.

54.   Antonicka H, Leary SC, Guercin GH, et al. Mutations in COX10 result in a defect in mitochondrial heme A biosynthesis and account for multiple, early-onset clinical phenotypes associated with isolated COX deficiency. Hum Mol Genet. 2003;12:2693–2702.

55.    Valnot I, Osmond S, Gigarel N, et al. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am J Hum Genet. 2000;67:1104–1109.

56.    Papadopoulou LC, Sue CM, Davidson MM, et al. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet. 1999;23:333–337.

57.    Leary SC, Sasarman F, Nishimura T, Shoubridge EA. Human SCO2 is required for the synthesis of CO II and as a thiol-disulphide oxidoreductase for SCO1. Hum Mol Genet. 2009;18:2230–2240.

58.    Mootha VK, Lepage P, Miller K, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative  genomics. Proc Natl Acad Sci U S A. 2003;100:605–610.

59.        Xu F, Morin C, Mitchell G, Ackerley C, Robinson BH. The role of the LRPPRC (leucine-rich pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: mutation causes lowered levels of COX (cytochrome c oxidase) I and COX III mRNA. Biochem J. 2004;382:331– 336.

60.   Ghezzi D, Saada A, D’Adamo P, et al. FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency. Am J Hum Genet. 2008;83:415–423.

61.    Weraarpachai W, Antonicka H, Sasarman F, et al. Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome  c oxidase deficiency and late-onset Leigh syndrome. Nat Genet. 2009;41:833–837.

62.   Weraarpachai W, Sasarman F, Nishimura T, et al. Mutations in C12orf62, a factor that couples COX I synthesis with cytochrome c oxidase assembly, cause fatal neonatal lactic acidosis. Am J Hum Genet. 2012;90:142–151.

63.    De Meirleir L, Seneca S, Lissens W, et al. Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. J Med Genet. 2004;41:120–124.

64.    Cizkova A, Stranecky V, Mayr JA, et al. TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy. Nat Genet. 2008;40:1288–1290.

65.   Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron- sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215– 217.

66.   Mochel F, Knight MA, Tong WH, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise    intolerance. Am J Hum Genet. 2008;82:652–660.

67.    Olsson A, Lind L, Thornell LE, Holmberg M. Myopathy with lactic acidosis is linked to chromosome 12q23.3–24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Hum Mol Genet. 2008;17:1666–1672.

68.    Rotig A, Mollet J, Rio M, Munnich A. Infantile and pediatric quinone deficiency diseases. Mitochondrion. 2007 Jun;7 Suppl:S112–S121.

69.        Duncan AJ, Bitner-Glindzicz M, Meunier B, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease.  Am J Hum Genet. 2009;84:558–566.

70.    Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet. 2008;82:623–630.

71.    Bogenhagen DF, Rousseau D, Burke S. The layered structure of human mitochondrial DNA nucleoids. J Biol Chem. 2008;283:3665–3675.

72.   Spinazzola A, Zeviani M. Disorders of nuclear-mitochondrial intergenomic communication. Biosci Rep. 2007;27:39–51.

73.   Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet. 2001;28:211–212.

74.   Longley MJ, Clark S, Yu Wai Man C, et al. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am J Hum Genet. 2006;78:1026–1034.

75.    Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289:782–785.

76.   Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet. 2001;28:223–231.

77.   Amati-Bonneau P, Valentino ML, Reynier P, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy “plus” phenotypes. Brain. 2008;131:338–351.

78.   Moraes CT, Shanske S, Tritschler HJ, et al. mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet. 1991;48:492–501.

79.        Sarzi E, Bourdon A, Chretien D, et al. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr. 2007;150:531–534, 534.

80.    Rotig A, Poulton J. Genetic causes of mitochondrial DNA depletion in humans. Biochim Biophys Acta. 2009;1792:1103–1108.

81.   Ferrari G, Lamantea E, Donati A, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA. Brain. 2005;128:723–731.

82.    Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol. 2004;55:706– 712.

83.   Mandel H, Szargel R, Labay V, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet. 2001;29:337–341.

84.   Spinazzola A, Viscomi C, Fernandez-Vizarra E, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38:570–575.

85.    Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet. 2001;29:342–344.

86.    Mancuso M, Salviati L, Sacconi S, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 2002;59:1197–1202.

87.   Gotz A, Isohanni P, Pihko H, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain.2008

88.    Bourdon A, Minai L, Serre V, et al. Mutation of RRM2B, encoding p53- controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39:776–780.

89.        Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet. 2005;76:1081–1086.

90.    Ostergaard E, Christensen E, Kristensen E, et al. Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am J Hum Genet. 2007;81:383–387.

91.    Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999;283:689–692.

92.    Tyynismaa H, Ylikallio E, Patel M, Molnar MJ, Haller RG, Suomalainen A.  A heterozygous truncating mutation in RRM2B causes autosomal- dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet. 2009;85: 290–295.

93.    Shaibani A, Shchelochkov OA, Zhang S, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol. 2009;66:1028–1032.

94.    Patton JR, Bykhovskaya Y, Mengesha E, Bertolotto C, Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem. 2005;280:19823–19828.

95.   Riley LG, Cooper S, Hickey P, et al. Mutation of the mitochondrial tyrosyl- tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia–MLASA syndrome. Am J Hum Genet. 2010;87:52– 59.

96.   Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl- tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007;39:534–539.

97.    Edvardson S, Shaag A, Kolesnikova O, et al. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet. 2007;81:857–862.

98.    Gotz A, Tyynismaa H, Euro L, et al. Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. Am J Hum Genet. 2011;88:635–642.

99.   Belostotsky R, Ben-Shalom E, Rinat C, et al. Mutations in the mitochondrial Seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. Am J Hum Genet. 2011;88:193–200.

100.   Pierce SB, Chisholm KM, Lynch ED, et al. Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc Natl Acad Sci U S A. 2011;108:6543–6548.

101.   Smeitink JA, Elpeleg O, Antonicka H, et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am J Hum Genet. 2006;79:869–877.

102.   Coenen MJ, Antonicka H, Ugalde C, et al. Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N Engl J Med. 2004;351:2080–2086.

103.   Valente L, Tiranti V, Marsano RM, et al. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am J Hum Genet. 2007;80:44–58.

104.   Miller C, Saada A, Shaul N, et al. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann Neurol. 2004;56:734–738.

105.   Saada A, Shaag A, Arnon S, et al. Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation. J Med Genet. 2007;44:784–786.

106.   Galmiche L, Serre V, Beinat M, et al. Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum Mutat. 2011;32:1225– 1231.

107.   Zeharia A, Shaag A, Pappo O, et al. Acute infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet. 2009;85: 401–407.

108.   Tucker EJ, Hershman SG, Kohrer C, et al. Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab. 2011;14:428–434.

109.   Crosby AH, Patel H, Chioza BA, et al. Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am J Hum Genet. 2010;87:655–660.

110.    Bouchet C, Steffann J, Corcos J, et al. Prenatal diagnosis of MELAS syndrome: contribution to understanding mitochondrial DNA segregation during human embryo fetal development. J Med Genet. 2006;43:788–792.

KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X